Medivir names Niklas Prager as new President and CEO
M2 - Mon Aug 11, 7:27AM CDT
Medivir AB (STO:MVIRB.ST), a research-based pharmaceutical company, announced today the appointment of Niklas Prager as new president and CEO of Medivir AB, effective 1 September 2014.
Niklas Prager Appointed New President and CEO of Medivir
Business Wire - Mon Aug 11, 3:18AM CDT
Regulatory News:
Medivir licenses Respiratory Syncytial Virus drug program from Boehringer Ingelheim
Business Wire - Mon Aug 04, 1:38AM CDT
Regulatory News:
Medivir: Phase II COSMOS Study Results Published in The Lancet on World Hepatitis Day
Business Wire - Mon Jul 28, 1:41AM CDT
Regulatory News:
Medivir reports global net sales of USD831m for Olysio during Q2 2014
M2 - Wed Jul 16, 3:38AM CDT
Medivir AB (OMX:MVIR), a research-based pharmaceutical company focused on infectious diseases, announced on Tuesday that the global second quarter 2014 net sales of Olysio (simeprevir) amounted to USD831m, out of which USD725m were sales in the US.
Medivir: U.S. FDA Has Granted Priority Review for OLYSIO(R) in Combination with sofosbuvir Supplementary New Drug Application
Business Wire - Tue Jul 15, 8:41AM CDT
Medivir (STO:MVIR-
Medivir: Continued strong market uptake for OLYSIO(R) during the second quarter 2014
Business Wire - Tue Jul 15, 7:11AM CDT
Regulatory News:
Medivir's OLYSIO to be available soon in all Nordic countries
M2 - Tue Jun 10, 8:00AM CDT
Medivir AB (OMX: MVIR), a research-based pharmaceutical company, announced today the availability of Olysio in all of the Nordic countries within the next few weeks for the treatment of adults with hepatitis C genotype 1 and 4 infection.
Medivir: OLYSIO(TM) available soon in all Nordic countries for the treatment of adults with hepatitis C genotype 1 and 4 infection
Business Wire - Tue Jun 10, 1:44AM CDT
Regulatory News:
Medivir's Simeprevir approved for treatment in Russia
M2 - Mon Mar 24, 5:26AM CDT
Medivir AB (STO:MVIRB.ST), a research-based pharmaceutical company focused on infectious diseases, announced today the approval by the Russian Ministry of Health of Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis.
Medivir: New Simeprevir data will be presented at The International Liver Congress 2014 of the European Association for the Study of the Liver, (EASL)
Business Wire - Mon Mar 24, 4:48AM CDT
Regulatory News:
Medivir: Simeprevir has now been approved in Russia
Business Wire - Mon Mar 24, 2:40AM CDT
Regulatory News:
Medivir: The Nomination Committee's Proposal, with Reference to the Upcoming 2014 Annual General Meeting, for a New Board of Directors
Business Wire - Fri Mar 14, 7:43AM CDT
Regulatory News:
Medivir: SVR12 Results from a Phase IIa Study Evaluating Simeprevir and Daclatasvir in Hepatitis C Patients of Genotype 1 Have Been Presented
Business Wire - Tue Mar 04, 11:30AM CST
Regulatory News: